MXCT News and Press, MaxCyte Inc. From 10/28/21

SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc....

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discov...

Gainers: MNTV +14.5%. AUTL +10.9%. QDEL +7.8%. APM +6.7%. OLED +5.6%. Losers: ALLO -33.5%. CLLS -18.9%. MXCT -16.1%. CDAK -5.8%. CRBU -5.8%. For further details see: MNTV, AUTL, ALLO and CLLS among after hours movers

MaxCyte (NASDAQ:MXCT) to join the Russell 3000 and Russell 2000 indices, effective after the U.S. market opens on September 20, 2021. "The addition of MaxCyte to the Russell indices highlights our strong financial profile and marks a milestone in our progress towards being the premier ce...

GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...

MaxCyte, Inc. (MXCT) Q2 2021 Earnings Conference Call September 13, 2021, 04:30 PM ET Company Participants Sean Menarguez - IR Doug Doerfler - CEO Amanda Murphy - CFO Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Co. Dan Arias - Stifel Matt Larew - Wil...

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disco...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. m...

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hyp...